Literature DB >> 22095540

Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.

Bastian A Vogl1, Ursula Fagin, Linda Nerbas, Peter Schlenke, Peter Lamprecht, Wolfram J Jabs.   

Abstract

Persistent Epstein-Barr virus (EBV) infection is controlled tightly by virus-specific T cells. EBV infection is reactivated intermittently over time, even in apparently healthy carriers. Changes in frequency and reactivity of memory T cells, particularly of CD8(+) origin, have not been assessed in this context. It is hypothesized that viral reactivation is facilitated by diminished EBV-specific T-cell immunity. To this end, blood samples from 14 healthy donors were collected at irregular time intervals for a period of about 1 year. Samples were screened for both EBV plasma viremia and increases in viral load in PBMCs as parameters of EBV reactivation. PBMCs were subject to IFN-γ ELISPOT analysis using the autologous EBV-transformed lymphoblastoid cell line (EBV-LCL) or appropriate HLA class I-restricted EBV peptides as stimulators. Frequencies of epitope-specific CD8(+) T cells were monitored further using HLA tetramers and flow cytometry. Twelve of 14 donors exhibited signs of asymptomatic EBV reactivation. Viral reactivation was accompanied by either substantially decreased IFN-γ responses against autologous EBV-LCL (eight of 12 study participants) and/or increased responses against particular EBV peptides (six of 12 donors). In seven persons with HLA-A2 and/or -B8 alleles numbers of HLA tetramer-positive CD8(+) T cells also varied over time, but showed no correlation to episodes of detectable viral activity. In summary, IFN-γ reactivity of EBV-specific T cells is not constant. Viral reactivation is detected preferably at times of diminished EBV-LCL-specific cellular immunity. However, increased reactivity of single immunodominant CD8(+) EBV-specific T-cell clones may occur in response to virus replication.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22095540     DOI: 10.1002/jmv.22258

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

1.  Epstein-Barr virus in oral shedding of children with multiple sclerosis.

Authors:  Carmen Yea; Raymond Tellier; Patrick Chong; Garrett Westmacott; Ruth Ann Marrie; Amit Bar-Or; Brenda Banwell
Journal:  Neurology       Date:  2013-09-06       Impact factor: 9.910

2.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

3.  Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.

Authors:  Rachele Ciccocioppo; Francesca Racca; Stefania Paolucci; Giulia Campanini; Lodovica Pozzi; Elena Betti; Roberta Riboni; Alessandro Vanoli; Fausto Baldanti; Gino Roberto Corazza
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study.

Authors:  Angela Chiereghin; Giulia Piccirilli; Tamara Belotti; Arcangelo Prete; Clara Bertuzzi; Dino Gibertoni; Liliana Gabrielli; Gabriele Turello; Eva Caterina Borgatti; Francesco Barbato; Mariarosaria Sessa; Mario Arpinati; Francesca Bonifazi; Tiziana Lazzarotto
Journal:  Med Microbiol Immunol       Date:  2019-07-09       Impact factor: 3.402

5.  Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease.

Authors:  Rachele Ciccocioppo; Francesca Racca; Luigia Scudeller; Antonio Piralla; Pietro Formagnana; Lodovica Pozzi; Elena Betti; Alessandro Vanoli; Roberta Riboni; Peter Kruzliak; Fausto Baldanti; Gino Roberto Corazza
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

6.  Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.

Authors:  Brett J Loechelt; Michael Green; Peter A Gottlieb; Emily Blumberg; Adriana Weinberg; Scott Quinlan; Lindsey R Baden
Journal:  J Pediatric Infect Dis Soc       Date:  2014-06-26       Impact factor: 3.164

7.  Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis.

Authors:  Rachele Ciccocioppo; Caterina Mengoli; Elena Betti; Giuditta Comolli; Irene Cassaniti; Antonio Piralla; Peter Kruzliak; Martin Caprnda; Lodovica Pozzi; Gino Roberto Corazza; Antonio Di Sabatino; Fausto Baldanti
Journal:  Clin Exp Med       Date:  2021-03-26       Impact factor: 3.984

8.  Herpesviruses and their genetic diversity in the blood virome of healthy individuals: effect of aging.

Authors:  Arttu Autio; Jalmari Kettunen; Tapio Nevalainen; Bryn Kimura; Mikko Hurme
Journal:  Immun Ageing       Date:  2022-03-12       Impact factor: 6.400

9.  Severe leptospirosis complicated by Epstein-Barr Virus reactivation.

Authors:  Matthias Karrasch; Konstantin Herfurth; Monika Kläver; Jenny Miethke; Anne Mayer-Scholl; Enno Luge; Eberhard Straube; Martin Busch
Journal:  Infection       Date:  2015-05-19       Impact factor: 7.455

10.  Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.

Authors:  Dae-Hee Sohn; Hyun-Jung Sohn; Hyun-Joo Lee; Seon-Duk Lee; Sueon Kim; Seung-Joo Hyun; Hyun-Il Cho; Seok-Goo Cho; Suk-Kyeong Lee; Tai-Gyu Kim
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.